

DOI: 10.21767/2572-5432.10034

Chronic Stress: Glucocorticoids and Metabolic Disturbances

Corrêa da Costa VM and Mousovich-Neto F

Endocrine Physiology Laboratory Doris Rosenthal (LFEDR), Carlos Chagas Filho Institute of Biophysics (IBCCF), Federal University of Rio de Janeiro (UFRJ), CCS, G block, University City, Fundão Island, Rio de Janeiro, Brazil

Corresponding author: VM Corrêa da Costa, Carlos Chagas Filho Institute of Biophysics, CCS G Block, University City, Fundão Island, Rio de Janeiro, Brazil. Tel: +55 21 2260-2364; E-mail: vmccosta@biof.ufrj.br**Rec date:** Nov 10, 2016; **Acc date:** Nov 17, 2016; **Pub date:** Nov 20, 2016**Copyright:** © 2016 Costa CD et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**Citation:** Corrêa da Costa VM, Mousovich-Neto F (2016) Chronic Stress: Glucocorticoids and Metabolic Disturbances. *J Clin Mol Endocrinol* 1: 34.

Letter to Editor

Defense mechanisms including behavioral and physiological adaptations are evoked in response to a potentially dangerous situation and are associated to the activation of hypothalamus-pituitary-adrenals (HPA) and sympatho-adrenal axes. Stress response affects different biological systems and includes increase in glucocorticoids serum levels (cortisol in humans and corticosterone in rodents). However, the persistent activation of hypothalamic-pituitary-adrenals axis, with the subsequent increase in glucocorticoid serum levels, is associated with metabolic disturbances such as the metabolic syndrome [1].

Anxiety is an important and prevalent mental disorders widespread around the world [2-3]. Frequently anxiety disorder is associated with activation of HPA axis resulting in increased serum glucocorticoid levels [4-5]. Glucocorticoid treatment has been shown to interfere in the pituitary response to thyrotropin releasing hormone (TRH), inducing a decrease in thyrotropin (TSH) secretion [6]. Thyroid hormone metabolism is also affected by glucocorticoids. In humans there are some studies suggesting a correlation between thyroidal disturbances and anxiety disorders [7-9]. In fact, Toyota et al., described a decrease in mRNA expression and type 2 iodothyronine deiodinase (D2) activity induced by glucocorticoids on the vascular bed; since D2 catalyzes the conversion of the pro-hormone T4 into T3, the biological active thyroid hormone, this decrease may affect vascular function [10].

Our previous studies demonstrated alterations in endocrine system and metabolic dysfunctions in a model of anxiety disorder in rats, including increases in the corticosterone and leptin serum levels [11]. We also detected abnormalities in thyroid function and regulation, since T3 serum levels were decreased while the TSH and T4 serum levels were normal. Body weight and food intake were unchanged, notwithstanding epididymal and retroperitoneal fat depots mass were around twice that of controls. Total cholesterol and triglycerides serum levels were increased in this rodent model of anxiety. Glucose tolerance test response and insulin serum levels were unchanged nevertheless fasting glycemia was elevated. Oxygen consumption was decreased as well as the BAT D2 activity [11]. Our data clearly associate anxiety with endocrine and metabolic dysfunctions mainly deriving from a HPA axis disturbance, and

support a possible relationship between chronic anxiety and the appearance of metabolic diseases. Taken together, these data suggest that other studies should be done in order for us to enhance knowledge between chronic anxiety, increased serum glucocorticoids, and metabolic dysfunctions relationship.

References

1. Paredes S, Ribeiro L (2014) Cortisol: the villain in metabolic syndrome? *Rev Assoc Med Bras* (1992) 60: 84-92.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62: 593-602
3. Andrade LH, Wang PY, Andreoni S, Silveira CM, Alexandrino-Silva C, et al. (2012) Mental Disorders in Mega Cities: Findings from the São Paulo Megacity Health Survey, Brazil. *PLoS ONE* 7: e31879.
4. Mantella RC, Butters MA, Amico JA, Mazumdar S, Rollman BL et al. (2008) Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. *Psychoneuroendocrinology* 33 :773-781.
5. Vreeburg SA, Zitman FG, van Pelt J, Derijk RH, Verhagen JCM, et al. (2010) Salivary Cortisol Levels in Person With and Without Different Anxiety Disorders. *Psychosom Med* 72 :340-347.
6. Brabant G, Brabant A, Ranft U, Ocran K, Kohrle J et al. (1987) Circadian and pulsatile thyrotropin secretion in euthyroid man under influence of thyroid hormone and glucocorticoid administration. *J Clin Endocrinol Metab* 65 :83-88.
7. Simon NM, Blacker D, Korbly NB, Sharma SG, Worthington JJ, et al. (2002) Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. *J Affect Disord* 69: 209-217.
8. Sanna L, Stuart AL, Pasco JA, Kotowicz MA, Berk M, et al. (2013) Physical comorbidities in men with mood and anxiety disorders: a population-based study. *BMC Med* 11: 110.
9. Arrojo E, Drigo R, Bianco AC (2011) Type 2 deiodinase at the crossroads of thyroid hormone action. *Int J Biochem Cell Biol* 43: 1432-1441.
10. Toyoda N, Yasuawaza-Amano C, Nomura E, Yamauchi A, Nishimura K, et al. (2009) Thyroid hormone activation in vascular smooth muscle cells is negatively regulated by glucocorticoids. *Thyroid* 19 :755-763.

11. Mousovich-Neto F, Lourenço AL, Landeira-Fernandez J, Corrêa da Costa VM (2015) Endocrine and metabolic function in male Carioca High-conditioned Freezing rats. *Physiol Behav* 142 : 90-96.